Alveron Pharma is developing a unique coagulation platform technology with the world’s first cyclodextrin-based anticoagulant reversal drug.
Alveron Pharma’s proprietary cyclodextrin-based compounds accelerate, but not initiate, coagulation via a unique mechanism. These compounds can therefore be used as systemic anti-bleeding agents, and our lead program is focused on developing a truly universal anticoagulant reversal agent.
History
Alveron Pharma was incorporated in March 2019 as a joint venture between Okklo Life Sciences, a company developing therapeutic cyclodextrins, and Sanquin, the Dutch Blood Supply Foundation, a world leader in coagulation research. Okklo is a privately held biopharmaceutical company developing novel therapeutic solutions in therapeutic areas with a high medical need using cyclodextrin-based technologies. The company was founded by a team of life-sciences experts previously involved in the development and approval of sugammadex (Bridion™), the first modified cyclodextrin marketed as a drug product.
Sanquin
Sanquin is an internationally highly respected research institute in the field of blood, transfusion, medicine and immunology, applying this knowledge to the development and manufacturing of a range of pharmaceutical and diagnostic products and services. Its core activities also comprise the safe and efficient production and distribution of blood and plasma products for the treatment of patients.
Alveron’s asset was developed jointly by Okklo and Sanquin.
